Was this page useful?

*Required Field

Research / UCCRI/ Publications


The following list is a selection of recently published, academic research articles collected by PubMed. All publications were authored by researchers affiliated with UCCRI.



Assessment of biochemical recurrence of prostate cancer (Review).

Lin X, Kapoor A, Gu Y, Chow MJ, Xu H, Major P, Tang D.

Int J Oncol. 2019 Oct 4. doi: 10.3892/ijo.2019.4893. [Epub ahead of print]



Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.

Hotte SJKapoor A, Basappa NS, Bjarnason G, Canil C, Conter HJ, Czaykowski P, Graham J, Gray S, Heng DYC, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, Patenaude F, Soulières D, Violette P, Winquist E, Wood LA, Dudani S, Maloni R, Reaume MN; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2019 Oct;13(10):343-354. doi: 10.5489/cuaj.6256. No abstract available.

PMID: 31603413


Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases.

Kapoor A, Wong NC, Wang Y, Mukherjee S, Hotte S, Dayes I, Lukka H.

Asian J Androl. 2019 Sep 13. doi: 10.4103/aja.aja_66_19. [Epub ahead of print] No abstract available.


Health-related quality of life by human immunodeficiency virus status in a cross-sectional survey of gay and bisexual prostate cancer survivors.

Polter EJ, Wheldon CW, Rosser BRS, Kohli N, Capistrant BD, Kapoor A, Konety B, Mittledorf D, Ross M, Talley KMC, Terveen L, West W, Wright MM.

Psychooncology. 2019 Sep 13. doi: 10.1002/pon.5228. [Epub ahead of print]



Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large Canadian multi-institutional database.

Oake JD, Patel P, Lavallée LT, Lattouf JB, Saarela O, Klotz L, Moore RB, Kapoor A, Finelli A, Rendon RA, Kawakami J, So A, Drachenberg DE.

Can Urol Assoc J. 2019 Jul 23. doi: 10.5489/cuaj.5941.



2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC).

Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North S, Pouliot F, Rendon R, Shayegan B, Sridhar S, So A, Usmani N, Vigneault E, Chi KN.

Can Urol Assoc J. 2019 Jun 25. doi: 10.5489/cuaj.6136. [Epub ahead of print] No abstract available.


Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis.

Nayan M, Jalali S, Kapoor A, Finelli A, So A, Rendon R, Breau RH, Lavallee LT, Tanguay S, Heng D, Kawakami J, Basappa NS, Bjarnason G, Pouliot F, Hamilton RJ.

Urol Oncol. 2019 Jul 5. pii: S1078-1439(19)30235-2. doi: 10.1016/j.urolonc.2019.06.006. [Epub ahead of print]



FAM84B promotes prostate tumorigenesis through a network alteration.

Jiang Y, Lin X, Kapoor A, He L, Wei F, Gu Y, Mei W, Zhao K, Yang H, Tang D.

Ther Adv Med Oncol. 2019 May 13;11:1758835919846372. doi: 10.1177/1758835919846372. eCollection 2019.



Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.

Mason RJ, Wood L, Kapoor A, Basappa N, Bjarnason G, Boorjian SA, Breau RH, Cagiannos I, Jewett MAS, Karakiewicz PI, Kassouf W, Kollmannsberger C, Lalani AA, Lattouf JB, Lavallée LT, Pautler S, Power N, Richard P, So A, Tanguay S, Rendon RA.

Can Urol Assoc J. 2019 Jun;13(6):166-174. doi: 10.5489/cuaj.5786. No abstract available.



Is nephrectomy no longer beneficial in the management of metastatic kidney cancer?

Kapoor A.

Can Urol Assoc J. 2019 Jun;13(6):151. doi: 10.5489/cuaj.6048. No abstract available.



Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2.

Wong ECL, Di Lena R, Breau RH, Pouliot F, Finelli A, Lavallée LT, So A, Tanguay S, Fairey A, Rendon R, Richard PO, Lattouf JB, Kawakami J, Mallick R, Kapoor A.

Urol Oncol. 2019 Jun 5. pii: S1078-1439(19)30195-4. doi: 10.1016/j.urolonc.2019.05.009. [Epub ahead of print]



High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex.

Trpkov K, Bonert M, Gao Y, Kapoor A, He H, Yilmaz A, Gill AJ, Williamson SR, Comperat E, Tretiakova M, Magi-Galluzzi C, Brimo F, Hes O.

Histopathology. 2019 Apr 19. doi: 10.1111/his.13876. [Epub ahead of print] No abstract available.



Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma.

Palumbo C, Cyr SJ, Mazzone E, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Shariat SF, Saad F, Simeone C, Briganti A, Kapoor A, Antonelli A, Karakiewicz PI.

J Endourol. 2019 Jul;33(7):606-613. doi: 10.1089/end.2019.0179. Epub 2019 May 17.


The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME.

Future Oncol. 2019 May;15(15):1683-1695. doi: 10.2217/fon-2018-0951. Epub 2019 Apr 10.



The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis.

Mei W, Lin X, Kapoor A, Gu Y, Zhao K, Tang D.

Cancers (Basel). 2019 Mar 27;11(4). pii: E434. doi: 10.3390/cancers11040434. Review.



The role and timing of cytoreductive nephrectomy in the immunotherapy era.

Wong ECL, Kapoor A.

Eur Urol Focus. 2019 Feb 26. pii: S2405-4569(19)30028-8. doi: 10.1016/j.euf.2019.02.008. [Epub ahead of print]



Upfront cytoreductive nephrectomy vs. upfront systemic therapy in metastatic kidney cancer.

Kapoor A, Wong ECL, Fang W, Wong NC.

Can Urol Assoc J. 2019 Feb 26. doi: 10.5489/cuaj.5666. [Epub ahead of print] No abstract available.



Canadian Urological Association guideline: Muscle-invasive bladder cancer.

Kulkarni GS, Black PC, Sridhar SS, Kapoor A, Zlotta AR, Shayegan B, Rendon R, Chung P, Van Der Kwast T, Alimohamed N, Fradet Y, Kassouf W.

Can Urol Assoc J. 2019 Jan 31. doi: 10.5489/cuaj.5902. [Epub ahead of print] No abstract available.



The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.

Bjarnason GA, Knox JJ, Kollmannsberger CK, Soulieres D, Ernst DS, Zalewski P, Canil CM, Winquist E, Hotte SJ, North SA, Heng DYC, Macfarlane RJ, Venner PM, Kapoor A, Hansen AR, Eigl BJ, Czaykowski P, Boyd B, Wang L, Basappa NS.

Eur J Cancer. 2019 Feb;108:69-77. doi: 10.1016/j.ejca.2018.12.006. Epub 2019 Jan 14.



Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol.

Breau RH, Cagiannos I, Knoll G, Morash C, Cnossen S, Lavallée LT, Mallick R, Finelli A, Jewett M, Leibovich BC, Cook J, LeBel L, Kapoor A, Pouliot F, Izawa J, Rendon R, Fergusson DA.

BMJ Open. 2019 Jan 3;9(1):e025662. doi: 10.1136/bmjopen-2018-025662.



SDH-deficient renal cell carcinoma - clinical, pathologic and genetic correlates: a case report.

Kumar R, Bonert M, Naqvi A, Zbuk K, Kapoor A.

BMC Urol. 2018 Nov 27;18(1):109. doi: 10.1186/s12894-018-0422-8.



Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Canil C, Kapoor A, Fu SYF, Choueiri TK, Heng DYC.

Cancer. 2018 Sep 15;124(18):3677-3683. doi: 10.1002/cncr.31595. Epub 2018 Oct 11.



Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.

Nazha S, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, Bjarnason GAG, Heng D, Soulières D, Reaume MN, Basappa N, Lévesque E, Dragomir A.

Clin Drug Investig. 2018 Dec;38(12):1155-1165. doi: 10.1007/s40261-018-0705-6.



Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence.

Saad F, Pouliot F, Danielson B, Catton C, Kapoor A.

Can Urol Assoc J. 2018 Sep;12(9):E415-E420. doi: 10.5489/cuaj.5154. Epub 2018 May 14. Review.



Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma.

Mazzone E, Nazzani S, Preisser F, Tian Z, Marchioni M, Bandini M, Capitanio U, Kapoor A, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, I Karakiewicz P.

Cancer Epidemiol. 2018 Oct;56:118-125. doi: 10.1016/j.canep.2018.08.006. Epub 2018 Aug 30.



Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.

Kassouf W, Monteiro LL, Drachenberg DE, Fairey AS, Finelli A, Kapoor A, Lattouf JB, Leveridge MJ, Power NE, Pouliot F, Rendon RA, Sabbagh R, So AI, Tanguay S, Breau RH.

Can Urol Assoc J. 2018 Aug;12(8):231-238. doi: 10.5489/cuaj.5462. Epub 2018 May 31. No abstract available.



External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, Kapoor A, Karam J, Kauffmann C, Klatte T, Ljungberg B, Matin S, Sjoberg D, Staehler M, Stewart GD, Tanguay S, Uzzo R, Welsh S, Wood L, Wood C, Bex A.

World J Urol. 2018 Dec;36(12):1973-1980. doi: 10.1007/s00345-018-2427-z. Epub 2018 Aug 1.


Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development.

Gu Y, Chow MJ, Kapoor A, Mei W, Jiang Y, Yan J, De Melo J, Seliman M, Yang H, Cutz JC, Bonert M, Major P, Tang D.

Transl Oncol. 2018 Aug;11(4):1012-1022. doi: 10.1016/j.tranon.2018.06.003. Epub 2018 Jun 30.



Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.

Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M.

Can Urol Assoc J. 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187.



Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells.

Al Saleh HA, Haas-Neill S, Al-Hashimi A, Kapoor A, Shayegan B, Austin RC, Al-Nedawi K.

Prostate. 2018 Sep;78(13):953-961. doi: 10.1002/pros.23653. Epub 2018 May 15.



The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy.

Marchioni M, Nazzani S, Preisser F, Bandini M, Tian Z, Kapoor A, Cindolo L, Primiceri G, Carmignani L, Briganti A, Montorsi F, Shariat SF, Schips L, Karakiewicz PI.

J Endourol. 2018 Jul;32(7):621-629. doi: 10.1089/end.2018.0025. Epub 2018 Jun 19.



Renal cell carcinoma in renal allograft: Case series and review of literature.

Vasisth G, Kapoor A, Piercey K, Lambe S.

Urol Ann. 2018 Apr-Jun;10(2):229-232. doi: 10.4103/UA.UA_66_17.



Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma.

Marchioni M, Harmouch SS, Nazzani S, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, Briganti A, Shariat SF, Schips L, Karakiewicz PI.

Cancer Epidemiol. 2018 Jun;54:112-118. doi: 10.1016/j.canep.2018.04.006. Epub 2018 May 16.



Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma.

Locke JA, Hamidizadeh R, Kassouf W, Rendon RA, Bell D, Izawa J, Chin J, Kapoor A, Shayegen B, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey AS, Jacobson NE, Drachenberg DE, Cagiannos I, So AI, Black PC.

Can Urol Assoc J. 2018 Aug;12(8):243-251. doi: 10.5489/cuaj.5377. Epub 2018 Apr 12.



The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis.

Bandini M, Marchioni M, Pompe RS, Tian Z, Martel T, Chun FK, Cindolo L, Kapoor A, Montorsi F, Shariat SF, Briganti A, Karakiewicz PI.

Can Urol Assoc J. 2018 Jul;12(7):E325-E330. doi: 10.5489/cuaj.4854. Epub 2018 Mar 19.



A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy.

Klotz L, Loblaw A, Siemens R, Ouellette P, Kapoor A, Kebabdjian M, Zhang L, Saad F; Canadian Urology Research Consortium.

J Urol. 2018 Aug;200(2):335-343. doi: 10.1016/j.juro.2018.03.010. Epub 2018 Mar 11.



The true malignancy risk of Bosniak III cystic renal lesions: Active surveillance or surgical resection?

Lam CJ, Kapoor A.

Can Urol Assoc J. 2018 Jun;12(6):E276-E280. doi: 10.5489/cuaj.4960. Epub 2018 Feb 23.



Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature.

Bandini M, Smith A, Marchioni M, Pompe RS, Martel TF, Cindolo L, Montorsi F, Shariat SF, Briganti A, Kapoor A, Capitanio U, Karakiewicz PI.

Clin Genitourin Cancer. 2018 Jun;16(3):176-183. doi: 10.1016/j.clgc.2018.01.003. Epub 2018 Feb 2. Review.



Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years.

Marchioni M, Preisser F, Bandini M, Nazzani S, Tian Z, Kapoor A, Cindolo L, Abdollah F, Tilki D, Briganti A, Montorsi F, Shariat SF, Schips L, Karakiewicz PI.

Eur Urol Focus. 2019 May;5(3):467-473. doi: 10.1016/j.euf.2018.01.007. Epub 2018 Feb 3.



Prostate cancer screening among family physicians in Ontario: An update on attitudes and current practice.

Akerman JP, Allard CB, Tajzler C, Kapoor A.

Can Urol Assoc J. 2018 Feb;12(2):E53-E58. doi: 10.5489/cuaj.4631. Epub 2017 Dec 1.



Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study.

Dragomir A, Aprikian A, Kapoor A, Finelli A, Pouliot F, Rendon R, Black PC, Moore R, Breau RH, Kawakami J, Drachenberg D, Lattouf JB, Tanguay S.

CMAJ Open. 2017 Dec 11;5(4):E834-E841. doi: 10.9778/cmajo.20170005.



Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.

Marchioni M, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, Primiceri G, Berardinelli F, Briganti A, Shariat SF, Schips L, Karakiewicz PI.

Eur Urol Focus. 2019 May;5(3):488-496. doi: 10.1016/j.euf.2017.11.012. Epub 2017 Dec 8.



The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT2-3 non-metastatic renal cell carcinoma treated with radical nephrectomy.

Marchioni M, Bandini M, Pompe RS, Martel T, Tian Z, Shariat SF, Kapoor A, Cindolo L, Briganti A, Schips L, Capitanio U, Karakiewicz PI.

BJU Int. 2018 Mar;121(3):383-392. doi: 10.1111/bju.14024. Epub 2017 Oct 12.



Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.

Marchioni M, Bandini M, Pompe RS, Tian Z, Martel T, Kapoor A, Cindolo L, Berardinelli F, Briganti A, Shariat SF, Schips L, Karakiewicz PI.

Int Urol Nephrol. 2017 Dec;49(12):2143-2149. doi: 10.1007/s11255-017-1703-y. Epub 2017 Sep 20.



Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer.

Danielson B, Saad F, So A, Morgan S, Hamilton RJ, Malone S, Park-Wyllie L, Zardan A, Shayegan B.

Can Urol Assoc J. 2019 Feb 7. doi: 10.5489/cuaj.5600. [Epub ahead of print] Review.



Development and acceptability testing of a patient decision aid for urinary diversion with radical cystectomy.

McAlpine K, Lavallée LT, Stacey D, Moodley P, Cagiannos I, Morash C, Black PC, Kulkarni GS, Shayegan B, Kassouf W, Siemens R, So A, Leveridge MJ, Boorjian SA, Daneshmand S, Smith AB, Power N, Izawa J, Drachenberg DE, Fairey A, Rendon RA, Breau RH.

J Urol. 2019 May 17:101097JU0000000000000341. doi: 10.1097/JU.0000000000000341. [Epub ahead of print]



Management algorithms for metastatic prostate cancer.

Malone S, Shayegan B, Basappa NS, Chi K, Conter HJ, Hamilton RJ, Hotte SJ, Saad F, So A, Park-Wyllie L, Hew H, McLeod D, Gotto G.

Can Urol Assoc J. 2019 Apr 26. doi: 10.5489/cuaj.5840. [Epub ahead of print] Review.



Patient centered care for prostate cancer-how can artificial intelligence and machine learning help make the right decision for the right patient?

Wong NC, Shayegan B.

Ann Transl Med. 2019 Mar;7(Suppl 1):S1. doi: 10.21037/atm.2019.01.13. No abstract available.



Exogenous estrogen therapy, testicular cancer, and the male to female transgender population: a case report.

Chandhoke G, Shayegan B, Hotte SJ.

J Med Case Rep. 2018 Dec 19;12(1):373. doi: 10.1186/s13256-018-1894-6.



Use of machine learning to predict early biochemical recurrence after robot-assisted prostatectomy.

Wong NC, Lam C, Patterson L, Shayegan B.

BJU Int. 2019 Jan;123(1):51-57. doi: 10.1111/bju.14477. Epub 2018 Aug 5.



Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces.

Woon DTS, Chandrasekar T, Aaron L, Basappa NS, Chi KN, Conter HJ, Gotto G, Hotte SJ, Malone S, Saad F, Shayegan B, Park-Wyllie L, Hamilton RJ.

Can Urol Assoc J. 2018 Oct;12(10):328-336. doi: 10.5489/cuaj.5378. Epub 2018 Jul 16.



Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.

Klotz L, Shayegan B, Guillemette C, Collins LL, Gotto G, Guérette D, Jammal MP, Pickles T, Richard PO, Saad F.

Can Urol Assoc J. 2018 Feb;12(2):30-37. doi: 10.5489/cuaj.5116. Epub 2017 Dec 19.



Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Kassouf W, Aprikian A, Saad F, Breau RH, Kulkarni G, Guttman DM, Bagshaw K, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Brimo F, Chung P, Drachenberg D, Fradet Y, Jacobsen N, Morash C, Shayegan B, Gotto G, Zlotta A, Fleshner N, Siemens DR, Black PC.

Can Urol Assoc J. 2018 Jul;12(7):E281-E297. doi: 10.5489/cuaj.5246. Epub 2018 Mar 19. No abstract available.



The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation.

Wallis CJD, Morton G, Herschorn S, Kodama RT, Kulkarni GS, Appu S, Shayegan B, Buckley R, Grabowski A, Narod SA, Nam RK.

Br J Cancer. 2018 May;118(10):1399-1405. doi: 10.1038/s41416-018-0071-4. Epub 2018 Mar 29.



High-intensity Focused Ultrasound (HIFU) as salvage therapy for radio-recurrent prostate cancer: predictors of disease response.

Dason S, Wong NC, Allard CB, Hoogenes J, Orovan W, Shayegan B.

Int Braz J Urol. 2018 Mar-Apr;44(2):248-257. doi: 10.1590/S1677-5538.IBJU.2017.0025.



Images in urology: Localized primary amyloidosis of the urinary bladder.

Varghese S, Wong NC, Shayegan B.

Can Urol Assoc J. 2018 Jan;12(1):E42-E44. doi: 10.5489/cuaj.4825. Epub 2017 Dec 1. No abstract available.



Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor.

Al-Hashimi AA, Lebeau P, Majeed F, Polena E, Lhotak Š, Collins CAF, Pinthus JH, Gonzalez-Gronow M, Hoogenes J, Pizzo SV, Crowther M, Kapoor A, Rak J, Gyulay G, D'Angelo S, Marchiò S, Pasqualini R, Arap W, Shayegan B, Austin RC.

J Biol Chem. 2017 Dec 22;292(51):21180-21192. doi: 10.1074/jbc.M117.799908. Epub 2017 Oct 24.



Overexpression of MUC1 and Genomic Alterations in Its Network Associate with Prostate Cancer Progression.

Lin X, Gu Y, Kapoor A, Wei F, Aziz T, Ojo D, Jiang Y, Bonert MShayegan B, Yang H, Al-Nedawi K, Major P, Tang D.

Neoplasia. 2017 Nov;19(11):857-867. doi: 10.1016/j.neo.2017.06.006. Epub 2017 Sep 18.



Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.

Shayegan B, Pouliot F, So A, Fernandes J, Macri J.

Can Urol Assoc J. 2017 Jun;11(6):204-209. doi: 10.5489/cuaj.4539. Review.


Towards development and validation of an intraoperative assessment tool for robot-assisted radical prostatectomy training: results of a Delphi study.

Morris C, Hoogenes J, Shayegan B, Matsumoto ED.

Int Braz J Urol. 2017 Jul-Aug;43(4):661-670. doi: 10.1590/S1677-5538.IBJU.2016.0420.



Contrast-enhanced Ultrasonography for Surveillance of Radiofrequency-ablated Renal Tumors: A Prospective, Radiologist-blinded Pilot Study.

Allard CB, Coret A, Dason S, Tajzler C, Shayegan B, Matsumoto ED, Kapoor A.

Urology. 2015 Dec;86(6):1174-8. doi: 10.1016/j.urology.2015.04.062. Epub 2015 Jun 26.



Utility of preoperative 3 Tesla pelvic phased-array multiparametric magnetic resonance imaging in prediction of extracapsular extension and seminal vesicle invasion of prostate cancer and its impact on surgical margin status: Experience at a Canadian academic tertiary care centre.

Lee T, Hoogenes J, Wright I, Matsumoto ED, Shayegan B.

Can Urol Assoc J. 2017 May;11(5):E174-E178. doi: 10.5489/cuaj.4211. Epub 2017 May 9.



Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline.

Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MA, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo P.

J Clin Oncol. 2017 Feb 20;35(6):668-680. doi: 10.1200/JCO.2016.69.9645. Epub 2017 Jan 17. Erratum in: J Clin Oncol. 2017 Apr 1;35(10):1141.



Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.

Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, van Rhijn BW, Fransen van de Putte EE, Zareba P, Koskinen I, Kassouf W, Traboulsi SL, Kukreja JE, Boström PJ, Shayegan B, Pinthus JH.

J Urol. 2016 Dec;196(6):1627-1633. doi: 10.1016/j.juro.2016.06.017. Epub 2016 Jun 14.



Prostate cancer, ESMO 2016.

Shayegan B.

Can Urol Assoc J. 2016 Nov-Dec;10(11-12Suppl6):S231-S234. doi: 10.5489/cuaj.4283. Review. No abstract available.



Contemporary agents in the management of metastatic castration-resistant prostate cancer.

Kapoor A, Wu C, Shayegan B, Rybak AP.

Can Urol Assoc J. 2016 Nov-Dec;10(11-12):E414-E423. doi: 10.5489/cuaj.4112. Epub 2016 Dec 12. Review.



How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer.

Wang Y, Dason S, Shayegan B.

Can J Urol. 2016 Aug;23(4):8388-94. Review.


Complete resection of a primitive neuroectodermal tumour arising in the bladder of a 31-year-old female after neoadjuvant chemotherapy.

Lam CJ, Shayegan B.

Can Urol Assoc J. 2016 Jul-Aug;10(7-8):E264-E267. doi: 10.5489/cuaj.3808. Epub 2016 Jul 12.



Impact of resident involvement in endoscopic bladder cancer surgery on pathological outcomes.

Bos D, Allard CB, Dason S, Ruzhynsky V, Kapoor A, Shayegan B.

Scand J Urol. 2016 Jun;50(3):234-8. doi: 10.3109/21681805.2016.1163616. Epub 2016 Apr 4.



Transurethral Resection of the Prostate Biopsy of Suspected Anterior Prostate Cancers Identified by Multiparametric Magnetic Resonance Imaging: A Pilot Study of a Novel Technique.

Dason S, Allard CB, Wright I, Shayegan B.

Urology. 2016 May;91:129-35. doi: 10.1016/j.urology.2015.12.063. Epub 2016 Feb 1.


Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Kassouf W, Aprikian A, Black P, Kulkarni G, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Alam T, Brimo F, Blais N, Booth C, Chin J, Chung P, Drachenberg D, Fradet Y, Jewett M, Moore R, Morash C, Shayegan B, Gotto G, Fleshner N, Saad F, Siemens DR.

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E46-80. doi: 10.5489/cuaj.3583. Epub 2016 Feb 8. No abstract available.



The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence.

Kapoor A, Dason S, Allard CB, Shayegan B, Lacombe L, Rendon R, Jacobsen NE, Fairey A, Izawa J, Black P, Tanguay S, Chin J, So A, Lattouf JB, Bell D, Saad F, Drachenberg D, Cagiannos I, Fradet Y, Alamri A, Kassouf W.

Can Urol Assoc J. 2014 Nov;8(11-12):E845-52. doi: 10.5489/cuaj.1985.



Laparoscopic management of advanced renal cell carcinoma with renal vein and inferior vena cava thrombus.

Bansal RK, Tu HY, Drachenberg D, Shayegan B, Matsumoto E, Whelan JP, Kapoor A.

Urology. 2014 Apr;83(4):812-6. doi: 10.1016/j.urology.2013.09.060. Epub 2014 Jan 8.



Endoplasmic reticulum protein ERp46 in prostate adenocarcinoma.

Duivenvoorden WCM, Hopmans SN, Austin RC, Pinthus JH.

Oncol Lett. 2017 May;13(5):3624-3630. doi: 10.3892/ol.2017.5908. Epub 2017 Mar 24.



Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor.

Al-Hashimi AA, Lebeau P, Majeed F, Polena E, Lhotak Š, Collins CAF, Pinthus JH, Gonzalez-Gronow M, Hoogenes J, Pizzo SV, Crowther M, Kapoor A, Rak J, Gyulay G, D'Angelo S, Marchiò S, Pasqualini R, Arap W, Shayegan BAustin RC.

J Biol Chem. 2017 Dec 22;292(51):21180-21192. doi: 10.1074/jbc.M117.799908. Epub 2017 Oct 24.



Endoplasmic reticulum protein ERp46 in renal cell carcinoma.

Duivenvoorden WC, Paschos A, Hopmans SN, Austin RC, Pinthus JH.

PLoS One. 2014 Mar 3;9(3):e90389. doi: 10.1371/journal.pone.0090389. eCollection 2014.



Comparison of clinical outcomes of laparoscopic versus open surgery for recurrent hepatocellular carcinoma: a meta-analysis.

Cai W, Liu Z, Xiao Y, Zhang W, Tang D, Cheng B, Li Q.

Surg Endosc. 2019 Jul 24. doi: 10.1007/s00464-019-06996-4. [Epub ahead of print]



Identifying and Codifying Complications after Radical Cystectomy: Comparison of Administrative Diagnostic and Procedure Codes and Clinical Chart Review.

Peyton CC, Reich RR, Tang D, Alford B, Azizi M, Li R, Sexton WJ, Poch M, Gilbert SM.

J Urol. 2019 Jun 20:101097JU0000000000000398. doi: 10.1097/JU.0000000000000398. [Epub ahead of print]



Potential effect of anti-inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy.

Kryvenko ON, Wang Y, Sadasivan S, Gupta NS, Rogers C, Bobbitt K, Chitale DA, Rundle A, Tang D, Rybicki BA.

Prostate. 2019 Jul;79(10):1090-1098. doi: 10.1002/pros.23820. Epub 2019 May 2.


Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.

Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM.

JAMA Oncol. 2018 Nov 1;4(11):1535-1542. doi: 10.1001/jamaoncol.2018.3542.



Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence.

Jiang Y, Mei W, Gu Y, Lin X, He L, Zeng H, Wei F, Wan X, Yang H, Major P, Tang D.

Mol Oncol. 2018 Sep;12(9):1559-1578. doi: 10.1002/1878-0261.12359. Epub 2018 Aug 11.



Upregulation of FAM84B during prostate cancer progression.

Wong N, Gu Y, Kapoor A, Lin X, Ojo D, Wei F, Yan J, de Melo J, Major P, Wood G, Aziz T, Cutz JC, Bonert M, Patterson AJ, Tang D.

Oncotarget. 2017 Mar 21;8(12):19218-19235. doi: 10.18632/oncotarget.15168.



Amplification of MUC1 in prostate cancer metastasis and CRPC development.

Wong N, Major P, Kapoor A, Wei F, Yan J, Aziz T, Zheng M, Jayasekera D, Cutz JC, Chow MJ, Tang D.

Oncotarget. 2016 Dec 13;7(50):83115-83133. doi: 10.18632/oncotarget.13073.



Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer.

Yan J, Ojo D, Kapoor A, Lin X, Pinthus JH, Aziz T, Bismar TA, Wei F, Wong N, De Melo J, Cutz JC, Major P, Wood G, Peng H, Tang D.

Cancer Res. 2016 Mar 15;76(6):1603-14. doi: 10.1158/0008-5472.CAN-15-1898. Epub 2016 Jan 21.



"High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.

He H, Trpkov K, Martinek P, Isikci OT, Maggi-Galuzzi C, Alaghehbandan R, Gill AJ, Tretiakova M, Lopez JI, Williamson SR, Montiel DP, Sperga M, Comperat E, Brimo F, Yilmaz A, Pivovarcikova K, Michalova K, Slouka D, Prochazkova K, Hora M, Bonert M, Michal M, Hes O.

Virchows Arch. 2018 Dec;473(6):725-738. doi: 10.1007/s00428-018-2456-4. Epub 2018 Sep 19.



Next Generation Quality: Assessing the Physician in Clinical History Completeness and Diagnostic Interpretations Using Funnel Plots and Normalized Deviations Plots in 3,854 Prostate Biopsies.

Bonert M, El-Shinnawy I, Carvalho M, Williams P, Salama S, Tang D, Kapoor A.

J Pathol Inform. 2017 Nov 23;8:43. doi: 10.4103/jpi.jpi_50_17. eCollection 2017.



Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.

Trpkov K, Hes O, Agaimy A, Bonert M, Martinek P, Magi-Galluzzi C, Kristiansen G, Lüders C, Nesi G, Compérat E, Sibony M, Berney DM, Mehra R, Brimo F, Hartmann A, Husain A, Frizzell N, Hills K, Maclean F, Srinivasan B, Gill AJ.

Am J Surg Pathol. 2016 Jul;40(7):865-75. doi: 10.1097/PAS.0000000000000617.



Eosinophilic, Solid, and Cystic Renal Cell Carcinoma: Clinicopathologic Study of 16 Unique, Sporadic Neoplasms Occurring in Women.

Trpkov K, Hes O, Bonert M, Lopez JI, Bonsib SM, Nesi G, Comperat E, Sibony M, Berney DM, Martinek P, Bulimbasic S, Suster S, Sangoi A, Yilmaz A, Higgins JP, Zhou M, Gill AJ, Przybycin CG, Magi-Galluzzi C, McKenney JK.

Am J Surg Pathol. 2016 Jan;40(1):60-71. doi: 10.1097/PAS.0000000000000508.



Anastomosing hemangioma of the kidney: radiologic and pathologic distinctions of a kidney cancer mimic.

Cheon PM, Rebello R, Naqvi A, Popovic S, Bonert M, Kapoor A.

Curr Oncol. 2018 Jun;25(3):e220-e223. doi: 10.3747/co.25.3927. Epub 2018 Jun 28.



Response of Primary Renal Cell Carcinoma to Systemic Therapy.

Bossé D, Lin X, Simantov R, Lalani AA, Derweesh I, Chang SL, Choueiri TK, McKay RR.

Eur Urol. 2019 Oct 5. pii: S0302-2838(19)30685-2. doi: 10.1016/j.eururo.2019.08.035. [Epub ahead of print]



Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma.

Lalani AA, Xie W, Braun DA, Kaymakcalan M, Bossé D, Steinharter JA, Martini DJ, Simantov R, Lin X, Wei XX, McGregor BA, McKay RR, Harshman LC, Choueiri TK.

Eur Urol Oncol. 2019 Sep 24. pii: S2588-9311(19)30142-7. doi: 10.1016/j.euo.2019.09.001. [Epub ahead of print]



State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era.

Bakouny Z, Flippot R, Braun DA, Lalani AA, Choueiri TK.

Eur Urol Focus. 2019 Feb 28. pii: S2405-4569(19)30049-5. doi: 10.1016/j.euf.2019.02.014. [Epub ahead of print] Review.



Systemic treatments for metastatic urothelial carcinoma.

Lalani AA, Sonpavde GP.

Expert Opin Pharmacother. 2019 Feb;20(2):201-208. doi: 10.1080/14656566.2018.1544242. Epub 2018 Nov 9. Review.


Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.

Lalani AA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, Wood C, Bex A.

Eur Urol. 2019 Jan;75(1):100-110. doi: 10.1016/j.eururo.2018.10.010. Epub 2018 Oct 13. Review.



Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.

Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I, Lundgren K, Bossé D, Van Allen EM, Choueiri TK, Rosenberg JE.

Br J Cancer. 2018 Sep;119(6):707-712. doi: 10.1038/s41416-018-0261-0. Epub 2018 Sep 17.



Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).

Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK.

Br J Cancer. 2018 May;118(11):1434-1441. doi: 10.1038/s41416-018-0087-9. Epub 2018 May 16.



The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.



Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, Choueiri TK.

Br J Cancer. 2018 May;118(9):1238-1242. doi: 10.1038/s41416-018-0064-3. Epub 2018 Apr 20.



Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.



Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.

Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK.

J Immunother Cancer. 2018 Jan 22;6(1):5. doi: 10.1186/s40425-018-0315-0.



Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.

Lalani AA, Gray KP, Albiges L, Callea M, Pignon JC, Pal S, Gupta M, Bhatt RS, McDermott DF, Atkins MB, Woude GFV, Harshman LC, Choueiri TK, Signoretti S.

Oncotarget. 2017 Oct 23;8(61):103428-103436. doi: 10.18632/oncotarget.21952. eCollection 2017 Nov 28.



JAVELIN: avelumab another spear to fight urothelial carcinoma.

Lalani AA, McGregor BA, Sonpavde GP, Choueiri TK.

Lancet Oncol. 2018 Jan;19(1):5-7. doi: 10.1016/S1470-2045(17)30901-4. Epub 2017 Dec 5. No abstract available.



Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.

Sevillano E, Werner L, Bossé D, Lalani AA, Wankowicz SAM, de Velasco G, Farina M, Lundgren K, Choueiri TK, González Del Alba A, Bellmunt J.

Clin Genitourin Cancer. 2017 Dec;15(6):e1089-e1094. doi: 10.1016/j.clgc.2017.07.012. Epub 2017 Aug 2.



Pan-urologic cancer genomic subtypes that transcend tissue of origin.

Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ.

Nat Commun. 2017 Aug 4;8(1):199. doi: 10.1038/s41467-017-00289-x.



Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.

Lalani AA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, Choueiri TK.

Clin Genitourin Cancer. 2017 Dec;15(6):724-732. doi: 10.1016/j.clgc.2017.05.019. Epub 2017 May 31.



First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.

Lalani AA, Li H, Heng DYC, Wood L, Kalirai A, Bjarnason GA, Sim HW, Kollmannsberger CK, Kapoor A, Hotte SJ, Vanhuyse M, Czaykowski P, Reaume MN, Soulieres D, Venner P, North S, Basappa NS.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):112-117. doi: 10.5489/cuaj.4398.



A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205.

Hotte SJ, Chi KN, Joshua AM, Tu D, Macfarlane RJ, Gregg RW, Ruether JD, Basappa NS, Finch D, Salim M, Winquist EW, Torri V, North S, Kollmannsberger C, Ellard SL, Eigl BJ, Tinker A, Allan AL, Beja K, Annala M, Powers J, Wyatt AW, Seymour L; Canadian Cancer Trials Group (formerly NCIC Clinical Trials Group).

Clin Genitourin Cancer. 2019 Jun;17(3):201-208.e1. doi: 10.1016/j.clgc.2019.03.005. Epub 2019 Mar 15.


Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer.

Beca J, Majeed H, Chan KKW, Hotte SJ, Loblaw A, Hoch JS.

Can Urol Assoc J. 2019 Apr 26. doi: 10.5489/cuaj.5889. [Epub ahead of print]



Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Morris MJ, Rumble RB, Basch E, Hotte SJ, Loblaw A, Rathkopf D, Celano P, Bangs R, Milowsky MI.

J Clin Oncol. 2018 May 20;36(15):1521-1539. doi: 10.1200/JCO.2018.78.0619. Epub 2018 Apr 2.



A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209.

Eigl BJ, Chi K, Tu D, Hotte SJ, Winquist E, Booth CM, Canil C, Potvin K, Gregg R, North S, Zulfiqar M, Ellard S, Ruether JD, Le L, Kakumanu AS, Salim M, Allan AL, Feilotter H, Theis A, Seymour L.

Oncotarget. 2018 Jan 17;9(8):8155-8164. doi: 10.18632/oncotarget.24263. eCollection 2018 Jan 30.



Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

Reaume MN, Basappa NS, Wood L, Kapoor A, Bjarnason GA, Blais N, Breau RH, Canil C, Cheung P, Conter HJ, Hotte SJ, Jeldres C, Jewett MAS, Karakiewicz PI, Kollmannsberger C, Patenaude F, So A, Soulières D, Venner P, Violette P, Zalewski P, Chappell H, North SA; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2017 Oct;11(10):310-320. doi: 10.5489/cuaj.4769. No abstract available.



A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.

Yu EY, Ellard SL, Hotte SJ, Gingerich JR, Joshua AM, Gleave ME, Chi KN.

Invest New Drugs. 2018 Apr;36(2):278-287. doi: 10.1007/s10637-017-0553-x. Epub 2017 Dec 18.



Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.

Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K.

Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.



Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.

Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, Hotte SJ, Tomlinson GA, Winquist E.

Ann Intern Med. 2017 Sep 5;167(5):341-350. doi: 10.7326/M16-2577. Epub 2017 Aug 8. Review.



Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.

Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, Hotte SJ, Winquist E; Cancer Care Ontario Genitourinary Cancer Disease Site Group.

Clin Oncol (R Coll Radiol). 2017 Jun;29(6):348-355. doi: 10.1016/j.clon.2017.01.007. Epub 2017 Feb 4. Review.



Chemotherapy research for metastatic prostate cancer.

Kapoor AHotte SJ.

Can Urol Assoc J. 2016 Aug;10(7-8Suppl3):S140-S143. Review. No abstract available.



Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.

Hotte SJ.

Future Oncol. 2017 Feb;13(4):369-379. doi: 10.2217/fon-2016-0279. Epub 2016 Oct 7. Review.



A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers.

Chi KN, Yu EY, Jacobs C, Bazov J, Kollmannsberger C, Higano CS, Mukherjee SD, Gleave ME, Stewart PS, Hotte SJ.

Ann Oncol. 2016 Jun;27(6):1116-22. doi: 10.1093/annonc/mdw068. Epub 2016 Feb 18.



Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.

Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL, Saad F.

Ann Oncol. 2015 Oct;26(10):2044-56. doi: 10.1093/annonc/mdv267. Epub 2015 Jun 22. Review.


The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).

Saad F, Chi KN, Finelli A, Hotte SJ, Izawa J, Kapoor A, Kassouf W, Loblaw A, North S, Rendon R, So A, Usmani N, Vigneault E, Fleshner NE.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):90-6. doi: 10.5489/cuaj.2526.



Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib.

Richter S, Seah JA, Pond GR, Gan HK, Mackenzie MJ, Hotte SJ, Mukherjee SD, Murray N, Kollmannsberger C, Heng D, Haider MA, Halford R, Ivy SP, Moore MJ, Sridhar SS.

Can Urol Assoc J. 2014 Nov;8(11-12):398-402. doi: 10.5489/cuaj.2426.



Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.

Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, De Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ; Abiraterone Global EAP Investigators.

Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2014 Nov;15(12):e528.



Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy.

Zareba P, Patterson L, Pandya R, Margel D, Hotte SJ, Mukherjee SD, Elavathil L, Daya D, Shayegan B, Pinthus JH.

Urol Oncol. 2014 Oct;32(7):975-80. doi: 10.1016/j.urolonc.2014.03.025. Epub 2014 Jul 11.



A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.

Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, Wong TS, Wang L, Ivy SP, Mukherjee SD, Kollmannsberger CK, Sukhai MA, Takebe N, Kamel-Reid S, Siu LL, Hotte SJ.

Invest New Drugs. 2014 Oct;32(5):1005-16. doi: 10.1007/s10637-014-0106-5. Epub 2014 May 3.



A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.

Azad AA, Beardsley EK, Hotte SJ, Ellard SL, Klotz L, Chin J, Kollmannsberger C, Mukherjee SD, Chi KN.

Invest New Drugs. 2014 Aug;32(4):746-52. doi: 10.1007/s10637-014-0091-8. Epub 2014 Mar 28.



Back to Top